EDC Solutions
-
Introducing One Home for Sites™
2/8/2024
One Home for Sites is a vendor-agnostic, sponsor-agnostic, aggregation platform that provides single sign-on and more. Become part of the only industry-wide solution to site tech overload.
-
SmartSignals Streamlines eClinical Workflows
8/16/2024
With robust APIs, detailed guides, and real-time monitoring, Signant SmartSignals Marketplace enhances eClinical workflows, minimizing duplication and ensuring reliable data across systems.
-
Medrio CDMS/EDC
10/5/2023
Discover how this intuitive user interface for data collection is improving maintenance control over the entire clinical study process, from database construction to the final report.
-
TrialKit eSource (Direct Data Capture)
6/6/2024
Gain confidence in your clinical research data with direct data capture (DDC).
-
It's Time To Move Into One Home for Sites
10/10/2024
Explore a vendor- and sponsor-neutral platform that streamlines trial management by consolidating systems and tasks.
-
Solutions For Clinical Data Review
12/17/2020
Revvity Signals Software’s Clinical Data Review solution provides those challenged with analyzing clinical data the ability to quickly spot outliers, dig deep into the data, and take questions to the next step.
-
Improving Trial Efficiency With eClinical Solutions
10/24/2023
Clinical development organizations looking for efficient, expedient, and agile technology solutions should see how leveraging an eClinical suite with unified solutions and a single database can drive efficiency.
-
Revvity Signals Software Risk-Based Monitoring Solution
8/28/2017
The Revvity Signals Software Risk-Based Monitoring Solution is the most effective way to leverage data-driven insights to optimize site performance while improving patient safety.
-
Democratizing Clinical Research With Castor
5/11/2023
Execute your study with Castor using modular solutions or as a platform package.
-
Efficiency, Flexibility, And Speed: Building Better Clinical Trials
9/19/2023
Zelta’s EDC has been used in more than 4,000 studies from startup to submission, across all phases, including over 500 phase 3c trials and 23 therapeutic areas.